The goal of this FOA is to establish functional genotype-phenotype relationships of genetic variants, suspected of altering the risk of Alzheimer's disease (AD), in neural cells using human induced pluripotent stem cells or other human cell reprogramming approaches. The causal linkage of AD-associated genetic variants identified in genome-wide association studies and genome sequencing studies to molecular and biological cell phenotypes in human neural cells is expected to give greater insight into molecular targets contributing to the etiology of AD. Studies of human genetics in human cells is essential to understanding the etiology of AD. Clinical trials are not permitted for this opportunity.
Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project
Letter of Intent Deadline: 30 days prior to application deadline
Application Deadline(s): Standard Dates for R01s 3/29/18 through 10/7/20